Home  |  Contact

UniProtKB/Swiss-Prot Q9BUM1: Variant p.Gly260Arg

Glucose-6-phosphatase 3
Gene: G6PC3
Variant information

Variant position:  260
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Arginine (R) at position 260 (G260R, p.Gly260Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Neutropenia, severe congenital 4, autosomal recessive (SCN4) [MIM:612541]: A disorder of hematopoiesis characterized by maturation arrest of granulopoiesis at the level of promyelocytes with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l and early onset of severe bacterial infections. {ECO:0000269|PubMed:19118303, ECO:0000269|PubMed:20220065, ECO:0000269|PubMed:20616219, ECO:0000269|PubMed:22050868, ECO:0000269|PubMed:22469094, ECO:0000269|PubMed:23018568, ECO:0000269|PubMed:23298686, ECO:0000269|PubMed:24105461, ECO:0000269|PubMed:24750412, ECO:0000269|PubMed:25492228}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In SCN4; complete loss of activity.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  260
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  346
The length of the canonical sequence.

Location on the sequence:   WIHVDSRPFASLSRDSGAAL  G LGIALHSPCYAQVRRAQLGN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         WIHVDSRPFASLSRDSGAALGLGIALHSPCYAQVRRAQLGN

Mouse                         WVHMDSRPFASLSRDSGSALGLGIALHTPCYAQIRRAHLGN

Rat                           WVLVDSRPFASLSRDSGSALGLGIALHTPCYAQIRRVHLGN

Bovine                        WVHLDSRPFASLSRDSGAALGLGIALHSPCYAQVRRAHLGY

Zebrafish                     WVRMDTAPFSSLNRDAGVLLGLGLAQ----YWKPGGWTLPR

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 346 Glucose-6-phosphatase 3
Transmembrane 255 – 273 Helical


Literature citations

Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.
McDermott D.H.; De Ravin S.S.; Jun H.S.; Liu Q.; Priel D.A.; Noel P.; Takemoto C.M.; Ojode T.; Paul S.M.; Dunsmore K.P.; Hilligoss D.; Marquesen M.; Ulrick J.; Kuhns D.B.; Chou J.Y.; Malech H.L.; Murphy P.M.;
Blood 116:2793-2802(2010)
Cited for: VARIANT SCN4 ARG-260; CHARACTERIZATION OF VARIANT SCN4 ARG-260;

Digenic mutations in severe congenital neutropenia.
Germeshausen M.; Zeidler C.; Stuhrmann M.; Lanciotti M.; Ballmaier M.; Welte K.;
Haematologica 95:1207-1210(2010)
Cited for: VARIANTS SCN4 LYS-116; GLN-189 AND ARG-260;

Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia.
Boztug K.; Rosenberg P.S.; Dorda M.; Banka S.; Moulton T.; Curtin J.; Rezaei N.; Corns J.; Innis J.W.; Avci Z.; Tran H.C.; Pellier I.; Pierani P.; Fruge R.; Parvaneh N.; Mamishi S.; Mody R.; Darbyshire P.; Motwani J.; Murray J.; Buchanan G.R.; Newman W.G.; Alter B.P.; Boxer L.A.; Donadieu J.; Welte K.; Klein C.;
J. Pediatr. 160:679-683(2012)
Cited for: VARIANTS SCN4 LEU-44; LYS-116; ILE-139; GLN-161; HIS-253; ARG-260 AND ASP-260;

Functional analysis of mutations in a severe congenital neutropenia syndrome caused by glucose-6-phosphatase-beta deficiency.
Lin S.R.; Pan C.J.; Mansfield B.C.; Chou J.Y.;
Mol. Genet. Metab. 114:41-45(2015)
Cited for: CHARACTERIZATION OF VARIANTS SCN4 LEU-44; SER-44; ILE-116; LYS-116; THR-116; VAL-116; ARG-118; ILE-139; PRO-154; GLN-161; PRO-185; GLN-189; ARG-208; HIS-253; ARG-260 AND ASP-260;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.